Details for New Drug Application (NDA): 203844
✉ Email this page to a colleague
NDA 203844 describes RIVASTIGMINE TARTRATE, which is a drug marketed by Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orbion Pharms, Sun Pharm, and Watson Labs, and is included in ten NDAs. It is available from eleven suppliers. Additional details are available on the RIVASTIGMINE TARTRATE profile page.
The generic ingredient in RIVASTIGMINE TARTRATE is rivastigmine tartrate. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the rivastigmine tartrate profile page.
The generic ingredient in RIVASTIGMINE TARTRATE is rivastigmine tartrate. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the rivastigmine tartrate profile page.
Summary for 203844
| Tradename: | RIVASTIGMINE TARTRATE |
| Applicant: | Cadila Pharms Ltd |
| Ingredient: | rivastigmine tartrate |
| Patents: | 0 |
Pharmacology for NDA: 203844
| Mechanism of Action | Cholinesterase Inhibitors |
Suppliers and Packaging for NDA: 203844
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 203844 | ANDA | Cadila Pharmaceuticals Limited | 71209-012 | 71209-012-03 | 60 CAPSULE in 1 BOTTLE (71209-012-03) |
| RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 203844 | ANDA | Cadila Pharmaceuticals Limited | 71209-012 | 71209-012-10 | 500 CAPSULE in 1 BOTTLE (71209-012-10) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 1.5MG BASE | ||||
| Approval Date: | Feb 13, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 3MG BASE | ||||
| Approval Date: | Feb 13, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 4.5MG BASE | ||||
| Approval Date: | Feb 13, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
